764 A phase 1, first-in-human (FIH), open-label, dose-finding and expansion study of XmAb808, a B7H3 x CD28 bispecific antibody, in combination with pembrolizumab in patients with advanced solid tumors

• Benjamin Thompson,
• Li Yao,
• Yana G Najjar,
• Siwen Hu-Lieskovan,
• Raphael Clynes,
• Bartosz Chmielowski,
• Mark N Stein,
• Sarina A Piha-Paul,
• Patricia McGovern,
• Judy S Wang,
• Benjamin Garmezy,
• Manojkumar Bupathi,
• Jitendra Kanodia

Affiliations

Benjamin Thompson

4 Liggins Institute, The University of Auckland, Auckland, New Zealand

Li Yao

Department of Nephrology, The first hospital of China Medical University, Shenyang, China

Yana G Najjar

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA

Siwen Hu-Lieskovan

Aff2 grid.19006.3e0000000096326718David Geffen School of Medicine at UCLA Los Angeles CA USA

Raphael Clynes

Aff126 grid.419971.3Bristol-Myers Squibb Lawrence Township NJ USA

Bartosz Chmielowski

20University of California Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA

Mark N Stein

Aff2 grid.430387.b0000000419368796Rutgers Cancer Institute of New Jersey New Brunswick NJ USA

Sarina A Piha-Paul

4Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Patricia McGovern

Douglas Macmillan Hospice, Stoke on Trent, UK

Judy S Wang

9Florida Cancer Specialists/SCRI, Sarasota, FL, USA

Benjamin Garmezy

1Sarah Cannon Cancer Institute Nashville, Nashville, TN, USA

Manojkumar Bupathi

1Sarah Cannon Research Institute at HealthONE, Denver, CO, USA

Jitendra Kanodia

10Xencor, Inc., Pasadena, CA, USA